251 related articles for article (PubMed ID: 18656238)
21. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
[TBL] [Abstract][Full Text] [Related]
22. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
Konstantinovsky S; Nielsen S; Vyberg M; Kvalheim G; Nesland JM; Reich R; Davidson B
Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
[TBL] [Abstract][Full Text] [Related]
23. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
[TBL] [Abstract][Full Text] [Related]
24. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
[TBL] [Abstract][Full Text] [Related]
25. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
26. Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors.
Kleinberg L; Pradhan M; Tropé CG; Nesland JM; Davidson B; Risberg B
Diagn Cytopathol; 2008 Sep; 36(9):637-44. PubMed ID: 18677760
[TBL] [Abstract][Full Text] [Related]
27. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
28. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
[TBL] [Abstract][Full Text] [Related]
29. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
30. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
Vaksman O; Davidson B; Tropé C; Reich R
Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
[TBL] [Abstract][Full Text] [Related]
31. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
[TBL] [Abstract][Full Text] [Related]
32. Nucleoside transporters are widely expressed in ovarian carcinoma effusions.
Bock AJ; Dong HP; Tropé CG; Staff AC; Risberg B; Davidson B
Cancer Chemother Pharmacol; 2012 Feb; 69(2):467-75. PubMed ID: 21822668
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
[TBL] [Abstract][Full Text] [Related]
34. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
35. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
[TBL] [Abstract][Full Text] [Related]
36. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
37. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.
Terauchi F; Okamoto A; Nagashima T; Kobayashi Y; Moritake T; Yamamoto Y; Takakura S; Iwaki S; Ogura H
Oncol Rep; 2005 Aug; 14(2):363-8. PubMed ID: 16012716
[TBL] [Abstract][Full Text] [Related]
39. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
40. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma.
Davidson B; Konstantinovsky S; Kleinberg L; Nguyen MT; Bassarova A; Kvalheim G; Nesland JM; Reich R
Gynecol Oncol; 2006 Sep; 102(3):453-61. PubMed ID: 16494928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
